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Abstract
Development of novel methodologies to efficiently create large genetic epidemiology cohorts is needed. Here we describe
a rapid, precise and cost-efficient method for collection of DNA from cases previously experiencing an osteoporotic fracture
by identifying cases using and administrative health-care databases. Over the course of 14 months we collected DNA from
1,130 women experiencing an osteoporotic fracture, at a cost of $54 per sample. This cohort is among the larger DNA
osteoporotic fracture collections in the world. The novel method described addresses a major unmet health care research
need and is widely applicable to any disease that can be identified accurately through administrative data.
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Introduction
Advances in genotyping technology have recently afforded
insights into the genetic determinants of common diseases through
the use of genome-wide association (GWA) studies [1]. GWA
studies have described common genetic variants which are
robustly associated with disease, but impart a relatively small risk.
Since these risks are small, but appear to be biologically relevant,
very large cohorts of disease cases and their controls are required
to identify the common genetic determinants that underpin
susceptibility to disease.
Although some prospective disease cohorts have collected DNA,
there still exists a need to enlarge these cohorts and associated
consortia to achieve adequate statistical power to identify the
genetic determinants of disease. Population-based longitudinal
prospective studies are able to address a myriad of important
scientific questions pertaining to the disease under study. However,
since modern genetic studies require very large populations of cases,
these longitudinal studies may not be able to provide a sufficient
number of cases. Now that genotyping technologies and method-
ologies are in place, novel methods that can efficiently assemble
large genetic epidemiology cohorts without having to re-create
longitudinal prospective cohorts are required.
In this paper, we demonstrate a novel method to efficiently create
a large genetic epidemiology cohort of osteoporotic fractures by
combining cases identified in a large administrative dataset using a
highly specific case definition with controls from a prospectively
followed population-based longitudinal cohort. To our knowledge,
thisgenetic cohortis amongthelargest osteoporoticfracture cohorts
worldwide. While we developed this cohort for osteoporotic
fractures, these methods are directly applicable to the assembly of
other genetic epidemiology disease cohorts.
Methods
We identified potential cases for the cohort using the administra-
tive data repository of Manitoba Health. We selected women who
had either a surgically repaired hip fracture, or a forearm fracture
with orthopedic reduction and/or casting using previously validated
definitions [2] between the ages of 45 and 70 years. Women with
known risk factors for osteoporotic fractures, indicators of significant
comorbidity, or those whose fracture resulted from severe trauma (as
indicated by trauma codes) were excluded.
Prior diagnoses were obtained from hospital discharge abstracts
and physician claims. We sought information on systemic
corticosteroid use from the province-wide pharmacy database
which captures virtually all prescription dispensations within the
province. This system maintains high-quality data on all
dispensations issued to Manitobans, such as drug, dosage, and
prescription date, with a high concordance between the prescrip-
tion claims database and pill counts [3].
Manitoba Health identified all women within 50 km of the city
of Winnipeg meeting our case definitions. A letter was sent by
Manitoba Health on behalf of the researchers to all subjects
inviting them to participate in the study. Individuals not
responding to the initial letter of invitation were sent a reminder
several weeks later. The researchers were unaware of the subjects’
identities until they contacted the research study office. Those
subjects agreeing to participate were mailed a salivary collection
kit in the regular post after the informed consent process. We
sought permission to re-contact individuals who had agreed to
participate in the study, and all but a dozen participants agreed.
This follow-up could be by phone, post or clinical visit. We do not
have permission to re-contact those who did not respond to our
initial invitation.
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tube using a standardized protocol (DNAGenotek Oragene,
Ottawa, Canada), which was then returned to the study laboratory
(Figure 1). Saliva can be collected from adults by following the
user instructions provided with the Oragene DNA self-collection
kit. It is also possible, however unlikely, that some subjects may not
be able to produce 2 ml of saliva. In this case, participant were can
be asked to perform a buccal swab, which is easier to perform and
also available from DNAGenotek. DNA was extracted using the
Qiagen QIAmp DNA mini kit as per the manufacturer’s
instructions. All samples were frozen at -80 Celsius to optimize
DNA storage [4]. DNA was quantified using ultra-violet
quantification. Salivary DNA collection enjoys several advantages,
including ease of collection, shipping and storage, high DNA
quality and relatively high DNA yields. See Rylander-Rudqvist et
al. 2006 [5], Rogers et al. 2007 [6], and Nishita et al. 2009 [7] for
details about quantity and quality of saliva DNA from Oragene
kit.
Data collection for the cases and controls included important
social and demographic information, and examined general
health, lifestyle, and medication use. Data on education level
and comorbid diagnoses (self-reported and physician-made) were
also collected.
Controls were selected from the Canadian Multicentre
Osteoporosis Cohort (CaMos), a longitudinal population-based
study following 9,423 randomly selected men and women from the
general Canadian population [8]. Controls were women 50 years
and older with current contact information, and not reporting a
prevalent fracture at baseline or during the 10 years of follow-up.
The rates of fracture in women in Manitoba are similar to those in
the rest of Canada [9].
Ethics approval: For both CaMos and the Manitoba Fracture
Cohort construction, the study was approved by regional
institutional ethics review boards, and participants provided
written informed consent. The study was reviewed and approved
by the Health Information Privacy Committee of Manitoba.
Results
In total, 7,826 women were identified by Manitoba Health as
meeting the fracture case definition and were sent a letter inviting
them to participate in the study. Among these potential
participants, 173 (2.2%) letters were returned, mostly because
the address was wrong, and 11 (0.1%) women were deceased. Of
the 7,642 contacted women, 7,149 (93.4%) had sustained a wrist
fracture and 502 (6.6%) a hip fracture. Of all the women
responding, 99.0% verified that they did indeed sustain the
osteoporotic fracture identified in the administrative data. The
specificity for the administrative case definition among women
contacted for reported hip and wrist fractures was 95.6% and
99.4%, respectively. To date, we have received DNA samples from
1,130 subjects (representing a response rate of 15.8%) of which
there were 84 (7.4%) hip fractures and 1,046 (92.6%) wrist
fractures. All samples were received within 14 months of initiating
the study. The mean age of the women participating from
Manitoba was 69.4 years (standard deviation [SD], 8.1) and the
vast majority were white. Table 1 describes the characteristics of
the cases and controls. The total cost of establishing the Manitoba-
McGill Fracture Genetics Cohort (not including costs associated
with DNA extraction) was $54 USD per sample.
For ethical reasons, the authors were not permitted to contact
women who decided not to participate in the study. Consequently,
we do not have information concerning the profile (administrative
and medical) of the non-respondents, besides their age.
Discussion
In summary, we have developed a novel paradigm for genetic
epidemiologic cohort creation. The method described is cost and
time efficient and identified cases with high precision.
Genetic epidemiology cohort creation using the above methods
is subject to several limitations. The first is that accurate and valid
administrative database codes need to be used to robustly identify
cases. Second, the response rate that we experienced in our cohort
creation was low. Nonetheless, the sampling frame was excep-
tionally large and therefore the absolute number of cases collect
was high. Indeed, the assembled cohort is now among the largest
DNA collections for fracture in the world. Third, the retrospective
design of sample collection is susceptible to survivorship bias;
wherein only those surviving the fracture would be eligible for
enrollment, possibly introducing selection bias. However, 93% of
the samples were collected from individuals experiencing a
forearm fracture, which has not been associated with increased
risk of mortality [10]. Hip fracture, on the other hand, has been
associated with 20% mortality at one year [11], however, targeted
age range of fracture (45–70 years) in our cohort is relatively low
Figure 1. Study Flow for the Manitoba Fracture Cohort.
doi:10.1371/journal.pone.0014045.g001
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mortality; therefore the survivorship bias in our cohort would be
reduced. Lastly, it is difficult to estimate the characteristics of the
non-responders since we were not allowed to contact them.
Fortunately, confounding due to compliance to participation
would be unlikely to influence the effect of genetic factors on risk of
fracture, since these factors would likely lie in the causal pathway.
In summary, this study design is widely applicable to common
diseases easily identifiable through administrative databases,
providing a novel paradigm for genetic epidemiology cohort
creation. Thus, this method addresses a compelling and unmet
health care research need by enabling researchers to efficiently
achieve an adequate number of cases for modern genetic
epidemiology studies.
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Table 1. Characteristics of the Manitoba Fracture Cohort Cases and Canadian Multicentre Osteoporosis Study (CaMos) Controls.
Variables Manitoba Fracture Cohort (Cases) CaMos (Controls)
Eligible women 7,149 5,566
DNA samples collected 1,130 (15.8%) 2,134 (38.3%)
Age 69.4 [8.14] 71.2 [9.8]
Fracture
Hip
Wrist
84 (7.4%)
1,046 (93.6%)
—
—
Race
White
Non white
700 (96.6%)
22 (3.4%)
5,361 (96.3%)
205 (3.7%)
Medication use after fracture
Bisphosphonates
Hormone replacement therapy
Raloxifene
Others
184 (60.7%)
94 (31.0%)
20 (6.6%)
5 (1.7%)
—
—
—
—
DNA quantity (ug) 242.1 [215.6] 177.6 [117.4]
Mean [SD] or Frequency (%).
doi:10.1371/journal.pone.0014045.t001
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